| Code | CSB-RA723415MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Mavrostobart, designed for research targeting NT5E (ecto-5'-nucleotidase), also known as CD73. NT5E is a cell surface enzyme that catalyzes the conversion of extracellular adenosine monophosphate to adenosine, playing a critical role in purinergic signaling and immune regulation. By generating adenosine in the tumor microenvironment, NT5E promotes immunosuppression through inhibition of T cell and natural killer cell function, while enhancing regulatory T cell activity. Elevated NT5E expression is associated with multiple cancers, including triple-negative breast cancer, melanoma, and ovarian cancer, where it correlates with poor prognosis and immune evasion.
Mavrostobart represents a therapeutic antibody approach aimed at blocking NT5E enzymatic activity to restore anti-tumor immunity. This biosimilar provides researchers with a valuable tool for investigating NT5E-mediated immunosuppression, studying adenosine pathway mechanisms in cancer and inflammation, and exploring combination strategies with other immunotherapies. It supports investigations into tumor microenvironment modulation and immune checkpoint research.
There are currently no reviews for this product.